|
|
 |
|
Viewing report
|
|
|
|
Treating COPD Comorbidities: A Market Opportunity for Systemic Anti-Inflammatory Agents?
Decision Resources, Inc., March 2008, Pages: 42
Executive Summary
Strategic Considerations
Stakeholder Implications
Introduction
Understanding the Mechanisms of COPD
Risk Factors for COPD
Pathophysiology of COPD
Small Airway Disease
Emphysema
Role of Systemic Inflammation in COPD
Comorbidities Associated with COPD Caused by Systemic Inflammation
Cardiovascular Complications: Atherosclerosis and Pulmonary Arterial Hypertension
Atherosclerosis
Pulmonary Arterial Hypertension
Osteoporosis
Type 2 Diabetes
Cachexia
Drug Classes with Possible Use in Treating the Systemic and Localized Infl ammation of COPD
TNF-a Inhibitors
PPAR-Gamma Agonists
Statins
PDE Inhibitors
Assessing the Unanswered Questions About Treating Systemic Inflammation in COPD
Appendix:Current Treatments for Localized COPD
Short-Acting Beta2 Agonists
Long-Acting Beta2 Agonists
Muscarinic Antagonists
Inhaled Corticosteroids
Beta2 Agonist/Muscarinic Antagonist Combinations
Long-Acting Beta2 Agonist/Inhaled Corticosteroid Combinations
Methylxanthines
Tables:
1. Sales of Leading Agents to Treat COPD, 2006
2. Risk Factors Linked to COPD
3. Inflammatory Molecules Involved in COPD
4. Existing and Emerging TNF-a Inhibitors, 2008
5. Existing and Emerging PPAR-Gamma Agonists, 2008
6. Approved Statins, 2008
7. Approved and Emerging PDE 4 and 5 Inhibitors, 2008
Figures:
1. Prevalent Cases of COPD in the United States, Europe, and Japan, 2006 and 2011
2. Comorbidities Associated with COPD
Customers who bought this item also bought
Asthma & COPD Therapeutics
Pipeline Insight: Asthma/COPD - Targeted Therapies on the Horizon
COPD - Another Reason to Quit
Chronic Obstructive Pulmonary Disease (COPD) Market: An Analysis
COPD Drug Discovery: How New Generation Therapies Seek to Target Underlying Disease
Asthma and COPD Drug Discoveries: What the Future Holds
Chronic Obstructive Pulmonary Disease (Copd) Update - Considerable Unmet Needs Invigorate Interest in the Copd Market
Commercial Insight: Asthma & COPD - Combination products still have blockbuster potential
Commercial Insight: Asthma & COPD - On the verge of generic entry
Commercial Insight: Asthma and Copd - Combinations breathe life into the asthma and Copd markets
U.S. COPD Market: Therapeutic Overview and Patient Outlook
U.S. COPD Market - Therapeutic Overview and Patient Outlook
|
|
|
|
